Cisplatin toxicity review

Author: bnfn

August undefined, 2024

WebFeb 22, 2024 · Cisplatin is a known nephrotoxic agent, so reducing its concentration to get a similar toxicity profile in NSCLC cells is advantageous. For the two normal lung cell lines ( Figure 4 A,B), while the Lipo-PEITC-CDDP caused the lowest survival percentages, 59.0 ± 15.7% and 71.5 ± 11.0% for WI-38 and BEAS-2B, respectively, the cytotoxic effect of ...

Cisplatin nephrotoxicity - PubMed

WebDec 1, 2024 · Dose adjustments for both docetaxel and cisplatin were performed according to pre-defined criteria for each type of toxicity (mainly grade 4 neutropenia and grade 3–4 neuropathy). Two dose reductions were allowed for DC75 (first to 60 mg/m 2, second to 50 mg/m 2), but only 1 reduction was allowed for DC60 and DCM therapy (to 50 mg/m 2). … WebSep 21, 2016 · Cisplatin produced superior response rates and survival in head and neck cancers. There are no published randomized phase III studies of bladder, cervical, endometrial, and esophageal cancers. CONCLUSION: Carboplatin does not possess equivalent activity to cisplatin in all platinum-sensitive tumors. c# types of variables

Side Effects of Cisplatin (Cisplatin Injection), Warnings, Uses - RxList

WebCisplatin is a clinically advanced and highly effective anticancer drug used in the treatment of a wide variety of malignancies, such as head and neck, lung, testis, ovary, breast cancer, etc. WebThe introduction of cisplatin to the clinic highlighted the hazards that follow failure to understand the renal complications of cytotoxic agents. 28 Effectively overcoming this principal toxicity of cisplatin has allowed … WebSep 27, 2024 · We conducted a systematic review to identify which genetic variants consistently associated with cisplatin-induced nephrotoxicity in oncology patients and assessed whether there are genetic variants that might be clinically relevant to guide cisplatin treatment. Methods c# types of functions

Cisplatin in cancer therapy: molecular mechanisms of action

Cisplatin Nephrotoxicity: A Review - Neil Kurtzman

WebOct 5, 2014 · Furthermore, combination therapies of cisplatin with other drugs have been highly considered to overcome drug-resistance and reduce toxicity. This comprehensive review highlights the physicochemical properties of cisplatin and related platinum-based drugs, and discusses its uses (either alone or in combination with other drugs) for the ... WebCisplatin is a widely used and highly effective cancer chemotherapeutic agent. One of the limiting side effects of cisplatin use is nephrotoxicity. Research over the past 10 years has uncovered many of the cellular mechanisms which … c type soilWebMar 2, 2024 · Cisplatin is a potent anticancer drug widely used for the treatment of several malignant tumors. One of the most relevant side effects of cisplatin is nephrotoxicity, that is very well-known since its introduction in 1978 and limits its use and efficacy [ 1, 2 ]. easing knee pain naturally

"WebThe cytotoxic activity in human cancer cell lines against colon adenocarcinoma (HCT-15), mammary adenocarcinoma (MCF-7), and lung adenocarcinoma (SKLU-1) was found comparable ((DAC) 2 Mg), or ca. 2-fold higher ((DAC) 2 Zn) than cisplatin. The acute toxicity assays indicate class 5 toxicity, according to the Organization for Economic Co ... " - Cisplatin toxicity review

Cisplatin toxicity review

Clinical comparative investigation of efficacy and toxicity of ...

WebSep 15, 2024 · SIDE EFFECTS. Nephrotoxicity - Dose-related and cumulative renal insufficiency is the major dose-limiting toxicity of cis-platin.Renal toxicity has been … WebCisplatin-induced kidney toxicity is reviewed here. The use of cisplatin in patients with pre-existing kidney dysfunction and the kidney effects of the platinum analogs, …

Did you know?

WebReview on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin Sara A. Aldossary Clinical pharmacy college, king faisal university Alhassa … WebThe TPF triplet regimen (docetaxel, cisplatin, and 5‐FU) has a trend of further improving treatment efficacy compared with the traditional doublet regimen. 35 , 36 In a phase II study, concurrent chemoradiotherapy with TPF achieved a clinical CR rate of 52.4%, much higher than the previously reported CR rate of 20%. 9 However, the high ...

WebAug 5, 2024 · Cisplatin is an FDA approved anti-cancer drug that is widely used for the treatment of a variety of solid tumors. However, the severe adverse effects of cisplatin, particularly kidney toxicity, restrict its clinical and medication applications. The major mechanisms of cisplatin-induced renal toxicit … WebApr 5, 2024 · Concurrent chemoradiotherapy with 3-weekly cisplatin 100 mg/m 2 has been the standard of care for locoregionally advanced head and neck cancer (LA-HNC) with level I evidence. While the outcomes in terms of efficacy have been well established, the toxicity profile, compliance, and real-world applicability has been an area of ongoing concern for …

WebMethods: This article examined a collection of studies suggesting that CYP450 enzymes may influence cisplatin toxicity. We performed a narrative mini-review. Results: The studies review showed that CYP450 enzymes have an important role in drug-induced hepatotoxicity and nephrotoxicity, mainly CYP2E1 and CYP4A11. WebThis systematic review and meta-analysis investigates 4 studies for the association of sodium thiosulfate with reduced risk of ototoxic effects among patients t ... A, Guerrero-Avendaño G, Zapata-Tarrés M, Medina-Sansón A. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and ...

WebDec 12, 2024 · This systematic review underlines some practice principles for cisplatin-induced nephrotoxicity. Therefore, at a cisplatin dosage of less than 50 mg/m 2, both short-duration and low volume hydration with normal saline prevent nephrotoxicity, as well as outpatient administration.

WebIntroduction: Cisplatin, a platinum-based antineoplastic agent, is the cornerstone for the treatment of many malignancies. Nephrotoxicity is the primary dose-limiting toxicity, … c# types of string literalsWebJun 1, 2016 · The carboplatin-docetaxel arm had a more favourable toxicity profile and a significant number of patients withdrew from the cisplatin-docetaxel doublet due to grade 3–4 emesis ( Greco et al., 2000 ). Other studies have observed the efficacy and tolerability of platinum-gemcitabine regimens in CUP. easing into retirementWebSep 15, 2024 · Cisplatin is mutagenic, teratogenic and carcinogenic and its use has been show to increase the risk of secondary malignancies, particularly leukemia. … easing knee painWebMar 28, 2024 · This study was conducted to evaluate the renal disease hirsutidin in the paradigm of renal toxicity induced by cisplatin. Male Wistar rats were given cisplatin (3 mg/kg body weight/day, for 25 ... easing market accessWebCisplatin has dramatically improved the survival rate of cancer patients, but it has also increased the prevalence of hearing and neurological deficits in this population. Cisplatin induces ototoxicity, peripheral (most prevalent) and central (rare) neurotoxicity. ctypes packageWebNov 12, 2024 · Commonly reported side effects of cisplatin include: bone marrow depression, nephrotoxicity, and ototoxicity. Continue reading for a comprehensive list of … easing lending standards bill blintonWebNov 26, 2024 · This review is mainly focused on four drugs: Cisplatin, Methotrexate, Doxorubicin, and Bleomycin, which belong to different CT groups—alkylating agents, antimetabolites and antitumor antibiotics, respectively. ... Cisplatin-Induced Toxicity . Cisplatin, cis- diamine-dichloro-platinum (CDDP) is one of the most used chemotherapy … easing job search stress